Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Nasus Pharma, Ltd.

Contributing Author

Recent Articles by Nasus Pharma, Ltd.

Aug-19
Nasus Pharma Announces Transition of Chief Financial Officer NSRX +5.21% GlobeNewswire
Aug-17
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update NSRX GlobeNewswire
Jul-28
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth NSRX GlobeNewswire
Jun-22
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum NSRX GlobeNewswire
Jun-09
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) NSRX GlobeNewswire
Jun-01
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis NSRX GlobeNewswire
May-01
Nasus Pharma to Participate in Upcoming Investor Conferences NSRX GlobeNewswire
Mar-25
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update NSRX +10.84% GlobeNewswire
Mar-16
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold NSRX -38.00% GlobeNewswire
Mar-09
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study NSRX -15.43% GlobeNewswire
Mar-09
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum NSRX -15.43% GlobeNewswire
Feb-20
Nasus Pharma to Participate in Upcoming Investor Conferences NSRX +18.00% GlobeNewswire
Feb-17
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 NSRX GlobeNewswire
Feb-13
Nasus Pharma Announces Closing of $15.0 Million Private Placement NSRX +5.36% GlobeNewswire
Feb-10
Nasus Pharma Announces Pricing of $15.0 Million Private Placement NSRX GlobeNewswire
Jan-20
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder NSRX -7.52% GlobeNewswire
Dec-22
Nasus Pharma CEO Issues 2025 Letter to Shareholders NSRX -6.56% GlobeNewswire
Nov-20
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer NSRX GlobeNewswire
Nov-18
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed NSRX GlobeNewswire
Nov-06
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder NSRX GlobeNewswire
Sep-02
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference NSRX GlobeNewswire
Aug-26
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony NSRX GlobeNewswire
Aug-14
Nasus Pharma Announces Closing of Initial Public Offering NSRX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)